Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab

Blinatumomab has demonstrated significant efficacy in adult and pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-cell ALL) and patients with measurable residual disease (MRD). This review aimed to compare median relapse-free survival (RFS) and median overall sur...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Hagop M. Kantarjian, Aaron C. Logan, Faraz Zaman, Nicola Gökbuget, Ralf C. Bargou, Yi Zeng, Gerhard Zugmaier, Franco Locatelli
Format:	Artigo
Sprog:	Inglês
Udgivet:	SAGE Publishing 2023-10-01
Serier:	Therapeutic Advances in Hematology
Online adgang:	https://doi.org/10.1177/20406207231201454
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!